Gilead Sciences (GILD) Q3 2026: Revenue Growth Amid Mixed Earnings — Cautiously Optimistic: Gaps +2.6% at Open — Post-Earnings Analysis

Gilead Sciences, Inc. (Nasdaq: GILD) reported its third-quarter 2026 financial results, revealing a total product sales increase of $1.0 billion or +13% year-over-year (YoY) to $8.3 billion. This growth was primarily driven by robust sales in the HIV segment, which saw an 18% increase, alongside notable contributions from oncology products like Trodelvy® and Livdelzi®. However, the quarter also presented challenges, particularly with a significant decline in Veklury® sales.

Key Financial Metrics:

• Total Product Sales: $8.3 billion, up $1.0 billion or +13% YoY
• Product Sales Excluding Veklury: $8.2 billion, up $1.1 billion or +16% YoY
• HIV Product Sales: $6.2 billion, up $900 million or +18% YoY
• Trodelvy Sales: $506 million, up $149 million or +42% YoY
• Diluted EPS: $1.94, down $0.49 or -20% YoY
• Non-GAAP Diluted EPS: $2.55, up $0.08 or +3% YoY
• Operating Cash Flow: $5.0 billion

Analyst View

This quarter can be viewed as a mixed bag for shareholders. On one hand, the revenue growth of 13% is commendable, particularly in the HIV segment, which continues to show resilience and demand. The increase in non-GAAP diluted EPS to $2.55 is also a positive sign, indicating that the core business is performing well despite the challenges faced in other areas.

However, the decline in diluted EPS to $1.94, primarily due to net losses from equity securities and increased operating expenses, raises concerns about profitability. The significant drop in Veklury sales, which fell 69% to $86 million, reflects the ongoing challenges in the COVID-19 treatment market as hospitalization rates decline. This decline in a previously strong revenue stream could impact future earnings if not offset by growth in other areas.

Dividend and Share Buyback

Gilead declared a quarterly dividend of $0.82 per share for the fourth quarter of 2026, payable on December 30, 2026. This reflects a commitment to returning value to shareholders, although it is essential to monitor the sustainability of this dividend in light of fluctuating earnings.

Guidance Update

Gilead has raised its full-year base business revenue guidance by $1.6 billion since the start of 2026, now expecting product sales to be between $31 billion and $31.3 billion. This upward revision is encouraging and suggests confidence in the company’s growth trajectory, particularly in the HIV and oncology segments.

Forward Catalysts

• New Product Launches: Gilead has multiple ongoing and potential launches in HIV and oncology, which could drive future revenue growth.
• Regulatory Approvals: The recent FDA approval for Bixlenvo™ for HIV treatment could enhance Gilead's market position and sales.
• Acquisition Integration: The successful integration of recent acquisitions, including PepStar Therapeutics, may provide additional growth avenues in inflammation and oncology.

In conclusion, while Gilead's third-quarter results show promising revenue growth, the decline in profitability metrics and reliance on specific product lines highlight the need for cautious optimism. The company’s ability to navigate these challenges while capitalizing on growth opportunities will be crucial for maintaining shareholder confidence moving forward.

GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

Note: Amounts in millions.

GILEAD SCIENCES, INC. CONDENSED CONSOLIDATED BALANCE SHEETS

Note: Amounts in millions.

Quarterly Earnings — Revenue vs. Estimate

Revenue vs. Estimate — 5 Quarters

EPS vs. Estimate — 5 Quarters

Technical Analysis — 90-Day Price Chart

Gilead Sciences Inc. (GILD) trades at $172.32, firmly above its key moving averages (SMA20: $154.54, SMA50: $150.64), confirming a strong bullish trend with no recent crossovers suggesting sustained upward momentum. The RSI(14) at 75.1 signals overbought conditions, indicating potential near-term consolidation or pullback risk. Volume at 3.56M shares is below the 20-day average of 5.87M, suggesting weaker conviction in the recent move. Positioned just 1.9% below its 52-week high ($175.65), GILD faces immediate resistance at this level, with support likely near the SMA20 or the 52-week low ($122.98) in a deeper correction. The stock’s proximity to all-time highs underscores bullish sentiment but warrants caution given overbought RSI and thinning volume.